-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HLzMV0VOztZ7fFO3GMuPZYgv9Ei9UDU8kIoBtmblVovGHLZ21w0sAvBBvxkrRcF2
 KTVxHcfKE1slnu9uZJonbw==

<SEC-DOCUMENT>0001144204-08-047299.txt : 20080814
<SEC-HEADER>0001144204-08-047299.hdr.sgml : 20080814
<ACCEPTANCE-DATETIME>20080814160921
ACCESSION NUMBER:		0001144204-08-047299
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080814
FILED AS OF DATE:		20080814
DATE AS OF CHANGE:		20080814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		081019092

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v123626_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title></head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      month of August, 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      X
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      X
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
      by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated August 14,
      2008
      is hereby incorporated by reference into the registration statements on Form
      F-3
      (File No. 333-141529 and File No. 333-147024) filed by XTL Biopharmaceuticals
      Ltd. with the Securities and Exchange Commission on March 23, 2007 and October
      30, 2007, respectively, and the registration statements on Form S-8 (File No.
      333-148058 and File No. 333-148574) filed by XTL Biopharmaceuticals Ltd. with
      the Securities and Exchange Commission on December 14, 2007 and January 18,
      2008, respectively.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Announces Appointment of Samuel H. Rudman to Board of
      Directors</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>VALLEY
      COTTAGE, NEW YORK, August 14, 2008 </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
      XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced that Samuel
      H.
      Rudman, Esq., has been appointed to XTL's Board of Directors, effective as
      of
      August 13, 2008.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr.
      Rudman, 40, is a named partner at a US law firm specializing in complex
      litigation, emphasizing securities, consumer, insurance, healthcare, human
      rights, employment discrimination and antitrust class actions. Mr. Rudman's
      practice is focused primarily on the area of securities and shareholder
      litigation, and complex issues of disclosure and corporate governance.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr.
      Rudman graduated with a BA in political science from Binghamton University
      and
      with a JD from Brooklyn Law School.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer of XTL, commented &#8220;We are excited to have Sam
      join our Board of Directors. Sam is well-versed in matters related to corporate
      governance. We believe that his skills provide a valuable addition to XTL's
      Board, as we prepare for the next stage of the company&#8217;s growth following what
      we hope will be a successful completion of our Phase 2b study of Bicifadine
      in
      Q4 2008.&#8221; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of diabetic neuropathic pain and HCV. XTL is developing
      Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
      of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has
      out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL
      also has an active in-licensing and acquisition program designed to identify
      and
      acquire additional drug candidates. XTL is publicly traded on the NASDAQ and
      Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">-2-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating future clinical and business prospects for our clinical compound
      for neuropathic pain, Bicifadine, growth and operating strategies and similar
      matters, may be forward-looking statements that involve a number of risks and
      uncertainties. For those statements, we claim the protection of the safe harbor
      for forward-looking statements contained in the Private Securities Litigation
      Reform Act of 1995. Among the factors that could cause our actual results to
      differ materially is our ability to complete in a timely and cost effective
      manner clinical trials on Bicifadine, which could directly impact our ability
      to
      continue to fund our operations; our ability to meet anticipated development
      timelines for all of our drug candidates due to recruitment, clinical trial
      results, manufacturing capabilities or other factors; our ability to obtain
      regulatory approvals for commercial sale of our products; the success of our
      drug development and marketing arrangements with third parties; and other risk
      factors identified from time to time in our reports filed with the Securities
      and Exchange Commission, including our annual report on Form 20-F filed with
      the
      Securities and Exchange Commission on March 27, 2008. Any forward-looking
      statements set forth in this press release speak only as of the date of this
      press release. We do not intend to update any of these forward-looking
      statements to reflect events or circumstances that occur after the date hereof.
      This press release and prior releases are available at http://www.xtlbio.com.
      The information in our website is not incorporated by reference into this press
      release and is included as an inactive textual reference only.
</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">-3-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
                BIOPHARMACEUTICALS LTD.</strong></font></div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                August 14, 2008</font></div>
            </td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bill
              Kessler</font></font></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bill
                  Kessler</font></div>
              </div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director
                  of Finance</font></div>
              </div>
            </td>
          </tr>

      </table><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">-4-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0V@17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P.#HP.#HQ
M-"`Q,#HS-#HS,0```````Z`!``,````!``$``*`"``0````!````J*`#``0`
M```!````2``````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```QJ````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`10"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]50<W+IPL._,OD4XU;[;($G:QIL?M']5
MJY_Z^T=<_8YZAT3+NQ\C!W66TTD?I:3_`#WM<UWZ:G;ZM7_7:_\`"+SCI?UT
MZK]K;7UK.MS.DY378^=6\C^9N'IOOK]-F[?3N]7V_F*7'A,X\0.VX_28YY!$
M@'KL78;_`(W>L?;?6=A8_P!@F3C@O];9_P"&=WI>K_Z#[/\`JUZABY-67BTY
M5!W4Y#&VUNXEKP'L/^:Y>7_^-+U`94/ZC0.ECW')@BWT^?H?S#7[/\+ZOIK'
MZK]=^K.S+/V/FVX/2<=K:<*FN(%%0].NQWJ,<_?=M]3_`,#4LL4,E#%6GS+!
M.4+]SJ='VU)>>95GUFZ1_B^R.J=0ZC>.J9+J+&EQ`-%;K:V,I'M_G7U/_6/^
MV_\`!KB/^>WUG_\`+F_[V?\`I-1QY<RNI#0TOEE$:L'5]Z27A`^N7UK(D=7R
M"#WEG_I-1/UU^M`,'K&0".02S_TFG?=)]PM^\1[%]Y27@[?KI]:7?1ZQD&/`
ML_\`2:[7_%AUSK'4\_J%?4<RW+9554ZL6$0"YUH<1M:W]U-GR\H1,B1HF.:,
MCPT7T-))!S'.9B7N82US:WEKAR"&G50@6:9":!/9,DN6^I'4<_..9]LO??Z8
MJV;XTW>KNB!^=M74I^7&<<S`FR*V\?4QX,PS8XY(@@2O?^J>%222Y?ZUN^L(
MS*?V3]H]+TCO]$`MW;N_\O:ECAQR$;$;ZRV3FR^U`SX3.OT8:R>H24*MWIMW
M3N@3/,PIIC(I))))3__0]57B?U[^K7[`ZR[T&1T[.W6XL<,/^'Q?^MN.^O\`
MX%Z]L7,_XQ6=+=]5<D]1);L+78A;&_[1Q0*P?I;O=ZO_`'7]92X)F,QVEH6/
M+`2B?#4/GC_KKF/^IC/J[+O7#O0??XX0$LIW3_._]I'_`/=1G_"(_P#B[^K!
MZSU7[?E,GIW3W!Q!'MMO'OJI_E,I_GKO^M+DC,:<_P`5[A]1;>E6?5?"_93=
ME+&[;6.(+Q<#^L^M'^$=;[_ZG\A6<Q]N!X17&=2PXOUD@9'Y1H'><UKA#@'#
MP.JCZ-7[C?N"FDJ+:?"/K=_XJ^K?^&7?]2Q>L?4>NMWU1Z27-!/V9FI`7D_U
MN_\`%7U;_P`,N_ZEB]:^HW_B0Z3_`.%F*WS'\U#Z?DU\/\Y-YO\`QO-:WIG3
M=K0/UIW`C_!/5#_%!_REU3_B*?\`J[EH_P"-_P#Y,Z;_`.&G?^>K%G?XH/\`
ME+JG_$4_]7<@/]S'^7Z23_/CR?4$#._H61_Q3_\`J2CH&=_0LC_BG_\`4E5H
M[CS99_*?(O"_5;K.-T?%S\B_W/<*6TT@PY[AZW^:QG^$L5M_UR^L`'VC["QN
M,=0YU=L1_P`?N:S_`**I?4SI]69U3?<T/KQ:_4#3J"\D-KG^K[WKT-7N9GBA
ME-X_<E*C+B-5I\L7+Y''GR<O&LIPPCQ"'"+,O5Q<4K<;H/UFQNKS46^AE-&X
MU$[@X?OU/]N[^4A?6+ZRV]&R*:68[;Q:PODO+8@AO[KESG6ZF]#^LM=^*/3K
MEF0UC=``XEE]8_D/VV?YZL_7_P#IV)_Q3O\`JVH1P8SFQD"\>6)EPGH0/E72
MYO,.7S`D#-@E&!D!\T9'25/:/OKJH=?<X5UL;N>XF`!$E<IE?7?)NR/0Z/B&
M[]USVN<YP'YS<>F'-;_6>I?7K-?7AXN$TD,NFRV.[:PW8W_/=O6O]6NEU].Z
M74-H&1>UMN0_N7.&X,G]VIIV-44(8\>(99QXS,D0AL-/TBS9,F7+G.#%+VXX
MP)9<E<4KE\L(N)5]=>I8MXKZM@[`=88U]3P/WFUY!=ZG^?6NKQ,O'S<=F3C/
M%E-@EKA^(/[KF_G(/5>FT=3PK,6X#W":W]V/'T+&_P!5<M]1,NVO,R>GO/M>
MTVAO86,(JM_[<:YG_;:)CCRXI3A'@GCKBB/EE$JC/+@SPQ9)^[CRWP3(J<9Q
M_1D__]'U5>+?7WZS_M[JYKQWSTW`+F8Y'#W_`$;\K^KIZ='_``7Z3_"KN/\`
M&/UW,P^F_LKIM5UF7GM(MMI8YWI4?1L.YC7?I;_YFO\`Z[9_HUP7U2^J>5UG
MK5.-E8UM.!3^ERS8Q]8-;3[<=I>UG](?^C_XGUE9Y>(B#DETV8,Q)(A'KN6=
MOU+S*_J;7]8R'>JY_JOH\,-PVU7[8_G-WZR__NI9_P`$B?4#ZS?L+K`Q\E^W
MIW4'-KO)XKM^C1D_R6_X*_\`D?I/\$O9'U5OJ=2]@=4YI8YA`+2TC:6%O[NU
M>'?67ZJYO1NKWX%./=?B'WXMC*WV`TN^C6Y[&N_24_S+_P#MQ/QY!E$H3ZZC
M^7]5$X>V8R@-M"^Z)+DO\7?7<S/Z5^S^I5VUYN``P/M8YGJT_1IMW6-;NL9_
M,W?]N_X5=:JDHF,B#T9P;%OA'UN_\5?5O_#+O^I8O6OJ-_XD.D_^%F+ROZV8
M.>_ZT]5?7BWO8[)<6N;4]P(AG#FL7JWU)8^OZI]*98TL>W'8'-<""#YM<K.<
MCVX?RZ,.$'CF\W_C?_Y,Z;_X:=_YZL6=_B@!_:/5#V]"G_J[EJ?XVL?(OZ;T
MX4567%N2XD5L<\@>F\?F!R\YHHZWCDNQJ<V@N$.-3+F$@=G;&MW)V./%@X;J
M_P"*,A,<O%1.G1^@D#.UPL@#_1/_`.I*\)]3ZS_O=2_]F$[7_68N:"[J1:7-
M#@?M$$$C=/\`931RU$>L*EGL$<$MGT;_`!?O8,G+8?I.KK<WX-+P[_JV+MEY
MMTO%ZSBOLZE@TOWXCFBRHL=+F/W;OT?M]6OV?I-GZ1G\XM9_^,!YJ+680&1P
M-UDM#OZ@8U[OZBEYGEYY,IECJ6PEK\A:/(\YCP\O&&:\9U,;C+UQXNE-7ZZ1
MD]?JQZ_<_P!*NDM'[SWO+6_YMC47Z_\`].Q/^*=_U;47ZN=$S\WJ7[:ZJUPA
MWJ5BP;7/L_,?Z?\`@Z:O\%_8_P`&H_7RFZS-Q376^P"ITEC2[\]O[H3H2B,V
M'&"#[49"1Z<4AJQY(3/+\QF,3'WYQE&)^;@C+TZ+?7ZI^_"M@[75/9Y2-KO^
M_+K>G7LR,#&OK,LLJ8X?-H57K/2*^K=-.,2&6MA]%A_->!W_`)+OH/7*8'6N
MK?5DG!SL8NHDEC'G;!.KOL]T/K?6[Z6Q0B/O88PB1[F,GT_O1E^ZV92^[<S/
M),'V<XCZP.+@G#]Y[Q[VL:7O,-:"7$]@%PWU+F[K]][1[/2L<3X;WLV)=0^L
M_4^NL/3^G8KF-MTL##O>X'\USX8RFIW^$_\`/BZ+ZM="_9&([U2'95Y#KB.`
M!]"EO\FN4>$X,,Q.N/+41#^KW*N,<US&*6,$XL%RED(H2D?T8V__TO54DDDE
M*22224I))))2DDDDE*22224I))))2E'8S=NVC=^]&JDDDI22222E)BUKA!`(
M\"G224L&M:(:`!X!.DDDI__3]527RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDD
MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9
M_^T23E!H;W1O<VAO<"`S+C``.$))300E```````0````````````````````
M`#A"24T#[0``````$`!(`````0`!`$@````!``$X0DE-!"8```````X`````
M````````/X```#A"24T$#0``````!````'@X0DE-!!D```````0````>.$))
M30/S```````)```````````!`#A"24T$"@```````0``.$))32<0```````*
M``$``````````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8`
M`0"AF9H`!@```````0`R`````0!:````!@```````0`U`````0`M````!@``
M`````3A"24T#^```````<```_____________________________P/H````
M`/____________________________\#Z`````#_____________________
M________`^@`````_____________________________P/H```X0DE-!```
M``````(``3A"24T$`@``````!``````X0DE-!`@``````!`````!```"0```
M`D``````.$))300>```````$`````#A"24T$&@`````#/0````8`````````
M`````$@```"H````!`!L`&\`9P!O`````0`````````````````````````!
M``````````````"H````2``````````````````````!````````````````
M`````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG````2`````!29VAT;&]N9P```*@````&<VQI8V5S5FQ,
M<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P``
M```````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E
M3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E
M5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`
M````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P``
M`$@`````4F=H=&QO;F<```"H`````W5R;%1%6%0````!````````;G5L;%1%
M6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585`````$`
M``````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$`
M``````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A
M=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E
M9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E
M`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO
M;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T
M;&]N9P``````.$))300H```````,`````3_P````````.$))3004```````$
M`````CA"24T$#``````,A@````$```"@````10```>```(%@```,:@`8``'_
MV/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2`
M`````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04
M#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,_\``$0@`10"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!````
M``````,``0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+
M$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52
MP6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S
M1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("
M`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A
M<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1
M`#\`]50<W+IPL._,OD4XU;[;($G:QIL?M']5JY_Z^T=<_8YZAT3+NQ\C!W66
MTTD?I:3_`#WM<UWZ:G;ZM7_7:_\`"+SCI?UTZK]K;7UK.MS.DY378^=6\C^9
MN'IOOK]-F[?3N]7V_F*7'A,X\0.VX_28YY!$@'KL78;_`(W>L?;?6=A8_P!@
MF3C@O];9_P"&=WI>K_Z#[/\`JUZABY-67BTY5!W4Y#&VUNXEKP'L/^:Y>7_^
M-+U`94/ZC0.ECW')@BWT^?H?S#7[/\+ZOIK'ZK]=^K.S+/V/FVX/2<=K:<*F
MN(%%0].NQWJ,<_?=M]3_`,#4LL4,E#%6GS+!.4+]SJ='VU)>>95GUFZ1_B^R
M.J=0ZC>.J9+J+&EQ`-%;K:V,I'M_G7U/_6/^V_\`!KB/^>WUG_\`+F_[V?\`
MI-1QY<RNI#0TOEE$:L'5]Z27A`^N7UK(D=7R"#WEG_I-1/UU^M`,'K&0".02
MS_TFG?=)]PM^\1[%]Y27@[?KI]:7?1ZQD&/`L_\`2:[7_%AUSK'4\_J%?4<R
MW+9554ZL6$0"YUH<1M:W]U-GR\H1,B1HF.:,CPT7T-))!S'.9B7N82US:WEK
MAR"&G50@6:9":!/9,DN6^I'4<_..9]LO??Z8JV;XTW>KNB!^=M74I^7&<<S`
MFR*V\?4QX,PS8XY(@@2O?^J>%222Y?ZUN^L(S*?V3]H]+TCO]$`MW;N_\O:E
MCAQR$;$;ZRV3FR^U`SX3.OT8:R>H24*MWIMW3N@3/,PIIC(I))))3__0]57B
M?U[^K7[`ZR[T&1T[.W6XL<,/^'Q?^MN.^O\`X%Z]L7,_XQ6=+=]5<D]1);L+
M78A;&_[1Q0*P?I;O=ZO_`'7]92X)F,QVEH6/+`2B?#4/GC_KKF/^IC/J[+O7
M#O0??XX0$LIW3_._]I'_`/=1G_"(_P#B[^K!ZSU7[?E,GIW3W!Q!'MMO'OJI
M_E,I_GKO^M+DC,:<_P`5[A]1;>E6?5?"_93=E+&[;6.(+Q<#^L^M'^$=;[_Z
MG\A6<Q]N!X17&=2PXOUD@9'Y1H'><UKA#@'#P.JCZ-7[C?N"FDJ+:?"/K=_X
MJ^K?^&7?]2Q>L?4>NMWU1Z27-!/V9FI`7D_UN_\`%7U;_P`,N_ZEB]:^HW_B
M0Z3_`.%F*WS'\U#Z?DU\/\Y-YO\`QO-:WIG3=K0/UIW`C_!/5#_%!_REU3_B
M*?\`J[EH_P"-_P#Y,Z;_`.&G?^>K%G?XH/\`E+JG_$4_]7<@/]S'^7Z23_/C
MR?4$#._H61_Q3_\`J2CH&=_0LC_BG_\`4E5H[CS99_*?(O"_5;K.-T?%S\B_
MW/<*6TT@PY[AZW^:QG^$L5M_UR^L`'VC["QN,=0YU=L1_P`?N:S_`**I?4SI
M]69U3?<T/KQ:_4#3J"\D-KG^K[WKT-7N9GBAE-X_<E*C+B-5I\L7+Y''GR<O
M&LIPPCQ"'"+,O5Q<4K<;H/UFQNKS46^AE-&XU$[@X?OU/]N[^4A?6+ZRV]&R
M*:68[;Q:PODO+8@AO[KESG6ZF]#^LM=^*/3KEF0UC=``XEE]8_D/VV?YZL_7
M_P#IV)_Q3O\`JVH1P8SFQD"\>6)EPGH0/E72YO,.7S`D#-@E&!D!\T9'25/:
M/OKJH=?<X5UL;N>XF`!$E<IE?7?)NR/0Z/B&[]USVN<YP'YS<>F'-;_6>I?7
MK-?7AXN$TD,NFRV.[:PW8W_/=O6O]6NEU].Z74-H&1>UMN0_N7.&X,G]VIIV
M-44(8\>(99QXS,D0AL-/TBS9,F7+G.#%+VXXP)9<E<4KE\L(N)5]=>I8MXKZ
MM@[`=88U]3P/WFUY!=ZG^?6NKQ,O'S<=F3C/%E-@EKA^(/[KF_G(/5>FT=3P
MK,6X#W":W]V/'T+&_P!5<M]1,NVO,R>GO/M>TVAO86,(JM_[<:YG_;:)CCRX
MI3A'@GCKBB/EE$JC/+@SPQ9)^[CRWP3(J<9Q_1D__]'U5>+?7WZS_M[JYKQW
MSTW`+F8Y'#W_`$;\K^KIZ='_``7Z3_"KN/\`&/UW,P^F_LKIM5UF7GM(MMI8
MYWI4?1L.YC7?I;_YFO\`Z[9_HUP7U2^J>5UGK5.-E8UM.!3^ERS8Q]8-;3[<
M=I>UG](?^C_XGUE9Y>(B#DETV8,Q)(A'KN6=OU+S*_J;7]8R'>JY_JOH\,-P
MVU7[8_G-WZR__NI9_P`$B?4#ZS?L+K`Q\E^WIW4'-KO)XKM^C1D_R6_X*_\`
MD?I/\$O9'U5OJ=2]@=4YI8YA`+2TC:6%O[NU>'?67ZJYO1NKWX%./=?B'WXM
MC*WV`TN^C6Y[&N_24_S+_P#MQ/QY!E$H3ZZC^7]5$X>V8R@-M"^Z)+DO\7?7
M<S/Z5^S^I5VUYN``P/M8YGJT_1IMW6-;NL9_,W?]N_X5=:JDHF,B#T9P;%OA
M'UN_\5?5O_#+O^I8O6OJ-_XD.D_^%F+ROZV8.>_ZT]5?7BWO8[)<6N;4]P(A
MG#FL7JWU)8^OZI]*98TL>W'8'-<""#YM<K.<CVX?RZ,.$'CF\W_C?_Y,Z;_X
M:=_YZL6=_B@!_:/5#V]"G_J[EJ?XVL?(OZ;TX4567%N2XD5L<\@>F\?F!R\Y
MHHZWCDNQJ<V@N$.-3+F$@=G;&MW)V./%@X;J_P"*,A,<O%1.G1^@D#.UPL@#
M_1/_`.I*\)]3ZS_O=2_]F$[7_68N:"[J1:7-#@?M$$$C=/\`931RU$>L*EGL
M$<$MGT;_`!?O8,G+8?I.KK<WX-+P[_JV+MEYMTO%ZSBOLZE@TOWXCFBRHL=+
MF/W;OT?M]6OV?I-GZ1G\XM9_^,!YJ+680&1P-UDM#OZ@8U[OZBEYGEYY,IEC
MJ6PEK\A:/(\YCP\O&&:\9U,;C+UQXNE-7ZZ1D]?JQZ_<_P!*NDM'[SWO+6_Y
MMC47Z_\`].Q/^*=_U;47ZN=$S\WJ7[:ZJUPAWJ5BP;7/L_,?Z?\`@Z:O\%_8
M_P`&H_7RFZS-Q376^P"ITEC2[\]O[H3H2B,V'&"#[49"1Z<4AJQY(3/+\QF,
M3'WYQE&)^;@C+TZ+?7ZI^_"M@[75/9Y2-KO^_+K>G7LR,#&OK,LLJ8X?-H57
MK/2*^K=-.,2&6MA]%A_->!W_`)+OH/7*8'6NK?5DG!SL8NHDEC'G;!.KOL]T
M/K?6[Z6Q0B/O88PB1[F,GT_O1E^ZV92^[<S/),'V<XCZP.+@G#]Y[Q[VL:7O
M,-:"7$]@%PWU+F[K]][1[/2L<3X;WLV)=0^L_4^NL/3^G8KF-MTL##O>X'\U
MSX8RFIW^$_\`/BZ+ZM="_9&([U2'95Y#KB.`!]"EO\FN4>$X,,Q.N/+41#^K
MW*N,<US&*6,$XL%RED(H2D?T8V__TO54DDDE*22224I))))2DDDDE*22224I
M))))2E'8S=NVC=^]&JDDDI22222E)BUKA!`(\"G224L&M:(:`!X!.DDDI__3
M]527RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9.$))300A``````!3`````0$`
M```/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$@!!`&0`;P!B
M`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P````$`.$))300&```````'
M``0````!`0#_X1?Y:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP
M86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y
M9"<_/@H\>#IX;7!M971A('AM;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAM
M<'1K/2=835`@=&]O;&MI="`S+C`M,C@L(&9R86UE=V]R:R`Q+C8G/@H\<F1F
M.E)$1B!X;6QN<SIR9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M
M+VE8+S$N,"\G/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED
M.C`S.#`P860R+39A,&4M,3%D9"UA8C`S+3@R,&%B-C0W868Y82<*("!X;6QN
M<SIE>&EF/2=H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R<^"B`@/&5X
M:68Z0V]L;W)3<&%C93XQ/"]E>&EF.D-O;&]R4W!A8V4^"B`@/&5X:68Z4&EX
M96Q81&EM96YS:6]N/C$V.#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@/&5X
M:68Z4&EX96Q91&EM96YS:6]N/C<R/"]E>&EF.E!I>&5L641I;65N<VEO;CX*
M(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2=U=6ED.C`S.#`P860R+39A,&4M,3%D9"UA8C`S+3@R,&%B-C0W868Y
M82<*("!X;6QN<SIP9&8])VAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\G
M/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70])W5U:60Z,#,X,#!A9#(M-F$P92TQ,61D+6%B,#,M.#(P86(V-#=A
M9CEA)PH@('AM;&YS.G!H;W1O<VAO<#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M:&]T;W-H;W`O,2XP+R<^"B`@/'!H;W1O<VAO<#I(:7-T;W)Y/CPO<&AO=&]S
M:&]P.DAI<W1O<GD^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TG=75I9#HP,S@P,&%D,BTV83!E+3$Q9&0M86(P
M,RTX,C!A8C8T-V%F.6$G"B`@>&UL;G,Z=&EF9CTG:'1T<#HO+VYS+F%D;V)E
M+F-O;2]T:69F+S$N,"\G/@H@(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z
M3W)I96YT871I;VX^"B`@/'1I9F8Z6%)E<V]L=71I;VX^-S(O,3PO=&EF9CI8
M4F5S;VQU=&EO;CX*("`\=&EF9CI94F5S;VQU=&EO;CXW,B\Q/"]T:69F.EE2
M97-O;'5T:6]N/@H@(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S
M;VQU=&EO;E5N:70^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TG=75I9#HP,S@P,&%D,BTV83!E+3$Q9&0M86(P
M,RTX,C!A8C8T-V%F.6$G"B`@>&UL;G,Z>&%P/2=H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C`O)SX*("`\>&%P.D-R96%T941A=&4^,C`P."TP."TQ-%0Q
M,#HS-#HS,2TP-3HP,#PO>&%P.D-R96%T941A=&4^"B`@/'AA<#I-;V1I9GE$
M871E/C(P,#@M,#@M,314,3`Z,S0Z,S$M,#4Z,#`\+WAA<#I-;V1I9GE$871E
M/@H@(#QX87`Z365T861A=&%$871E/C(P,#@M,#@M,314,3`Z,S0Z,S$M,#4Z
M,#`\+WAA<#I-971A9&%T841A=&4^"B`@/'AA<#I#<F5A=&]R5&]O;#Y!9&]B
M92!0:&]T;W-H;W`@0U,@5VEN9&]W<SPO>&%P.D-R96%T;W)4;V]L/@H@/"]R
M9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M)W5U:60Z,#,X,#!A9#(M-F$P92TQ,61D+6%B,#,M.#(P86(V-#=A9CEA)PH@
M('AM;&YS.GAA<$U-/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO
M)SX*("`\>&%P34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W`Z
M,#,X,#!A9#$M-F$P92TQ,61D+6%B,#,M.#(P86(V-#=A9CEA/"]X87!-33I$
M;V-U;65N=$E$/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70])W5U:60Z,#,X,#!A9#(M-F$P92TQ,61D+6%B,#,M
M.#(P86(V-#=A9CEA)PH@('AM;&YS.F1C/2=H='1P.B\O<'5R;"YO<F<O9&,O
M96QE;65N=',O,2XQ+R<^"B`@/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF
M;W)M870^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F.E)$1CX*/"]X.GAM
M<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^_^(,6$E#0U]04D]&24Q%``$!
M```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S<$U31E0`
M````245#('-21T(``````````````````/;6``$`````TRU(4"`@````````
M```````````````````````````````````````````````````````18W!R
M=````5`````S9&5S8P```80```!L=W1P=````?`````48FMP=````@0````4
M<EA96@```A@````49UA96@```BP````48EA96@```D`````49&UN9````E0`
M``!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P```]0````D;'5M:0``
M`_@````4;65A<P``!`P````D=&5C:```!#`````,<E120P``!#P```@,9U12
M0P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`````````$G-21T(@
M245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V,3DV-BTR+C$`````
M````````````````````````````````````````````````````````````
M`%A96B````````#S40`!`````1;,6%E:(`````````````````````!865H@
M````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:6%E:(```````
M`"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M`````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````````````
M````````````````````````````````````````````9&5S8P`````````N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M```````````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="`````````````````````````````&1E<V,`````````
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`
M`````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ``````````````````````````````````!V:65W```````3
MI/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@``````!,"58`4````%<?
MYVUE87,``````````0````````````````````````*/`````G-I9R``````
M0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[`$``
M10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R
M`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!
M,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1
M`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"
MH@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6
M`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$
MQ`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86
M!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'
MK`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED
M"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+
M:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.
M#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0
M"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C
M$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5
MFQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO
M&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<
M*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_
M'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0C
MPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<
M*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL
M;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2
M,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV
M-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK
M.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!
M*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P
M1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-
M2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J
M4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:
MIEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B
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M9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--
MD[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<
M]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+
MIOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6P
MZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LN
MNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&
M1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\
MT;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=
M$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\
MZ4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U
M4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`#D%D
M;V)E`&0``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$'!P<-#`T8$!`8
M%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,_\``$0@`2`"H`P$1``(1`0,1`?_=``0`%?_$`:(````'`0$!
M`0$```````````0%`P(&`0`'"`D*"P$``@(#`0$!`0$``````````0`"`P0%
M!@<("0H+$``"`0,#`@0"!@<#!`(&`G,!`@,1!``%(1(Q05$&$V$B<8$4,I&A
M!Q6Q0B/!4M'A,Q9B\"1R@O$E0S13DJ*R8W/"-40GDZ.S-A=49'3#TN(()H,)
M"A@9A)1%1J2T5M-5*!KRX_/$U.3T976%E:6UQ=7E]69VAI:FML;6YO8W1U=G
M=X>7I[?'U^?W.$A8:'B(F*BXR-CH^"DY25EI>8F9J;G)V>GY*CI*6FIZBIJJ
MNLK:ZOH1``("`0(#!04$!08$"`,#;0$``A$#!"$2,4$%41-A(@9Q@9$RH;'P
M%,'1X2-"%5)B<O$S)#1#@A:24R6B8[+"!W/2->)$@Q=4DP@)"A@9)C9%&B=D
M=%4W\J.SPR@IT^/SA)2DM,34Y/1E=865I;7%U>7U1E9F=H:6IK;&UN;V1U=G
M=X>7I[?'U^?W.$A8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZ
MRMKJ^O_:``P#`0`"$0,1`#\`]4XJMDD2.-I)#Q1`69CV`%2<5?,>N?\`.6>O
MC79#HNE6AT2*0K&MSZAGFC!IS+*RK%S&ZKP?C_E9M8=G"MSZG6SUQO8;/H/R
M5YLL/-OE>P\P6*M'!?1\C"Y!:-U)21&I_(ZLN:[+C,)&)<_',2%A.\K9NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O__0[1^=9\]VOE&36/)VH26E
MYI?*:\MDCBD]:VI^\($B/\<5/4'']GG_`).9&FX#*I#8M&HXN&XGD^=O+W_.
M0WYA0:U:2:]JC:EHA?AJ-DT,"\X''&3B41&Y*IY)\7VLV<]%"O2*DZ^&KG>Y
MV3/4/^<8O.,VIH_ERZL[_P`NWE)K'49)N!%O)\2&1.)9CP/6/ER_R<C'7QKU
M;292T4B=OI6>;_S)USR"]EY%\DZMZ5IY?B:'4KY(XG^LWTCF2<@2*_%(V/!0
M/\K''@&2YS'U?[E<N8XZC$_2]#_(WS!^:7F33=5\S>8-9EET>VAFBT^`Q0()
MKA5):2JQJW"'[/7XI/\`4S&U4,<2(Q&[D::<Y`R)V>-+_P`Y`?F[Q'_.Q/T_
MWQ;?]4LS?R>+N<,ZK)WM_P#*_P#\W?\`J8G_`.1%M_U2Q_)XNY'YK)WN_P"5
M_?F[_P!3$_\`R(MO^J6/Y/%W+^:R=[7_`"O_`/-S_J8G_P"1%M_U2Q_)XNY?
MS63O<?S^_-ZA_P"=BD_Y$6W_`%2Q_)XNY1JLG>^U=/D>6PMI)#R=XD9V\25!
M)S1GF[D<E?`EYW^<7FC7=!MM+?2;HVK3O*LQ"HW(*JD?;#=*YM.R]/#*9<8N
MJ>?[?UN7!&!QGAXB67^5+RYO?+.EWET_J7%Q:Q232$`<G9`2:"@ZY@ZB`CDD
M!R$B[;19#/#"4OJE&,DURERG8J\I?S'YZ'YF_H\27/Z#^NK'Q]`>EZ5!7]YP
M^S_E<LW(P8/RW%MXG#_.>9EJM5^=X/5X/'_-]/#_`%J>K9IGIG8J[%78J__1
M]4LH8%6%5.Q!Z$8J^+/SV_+4^2O-SR64970=6+7&G$#X8VK66#_GF35/^*V7
M^7-[I,_''?Z@Z?58>"5CD61>0OS\G\O?E5J6A2N6URRI#Y><@G]U/6I)_P"7
M4\G7E]KDB?LY5FTG%D!_A_B;,6JX8$=?X7G'D+R;JGG?S;:Z+;,Q>Y<RWUV?
MB,<(-996)ZMO\/\`-(RYE9LHQQMQL6,SE3[IT?0M+T?1;;1;"!8].M(1!%!U
M'`"AY?S%NK_S9S\I$FSS=W&(`H):/RZ_+\"@\M:7_P!(<'_-&2\:?>?FQ\*'
M<'S[_P`Y4^7M!T>Y\MC2--M=/$R7?K"UACAY\3%QY<`O*E32N;+03,@;-N!K
MH`500_\`SBSH.AZQK/F"/5M/MM0CBMH&B2ZA28(3(X)4.&XDT[8=?.0`HTC1
M1!)L/HB7\N_(/I/3RWI8/$[_`%.#P_U,UOC3[S\W8>%#N#X'FV9P.E3^O.B=
M%U?HEI?_`!S+3_C#'_Q`9S)YO0#DB<"7DWY__P"\>C?\9)_^(IF[[%^J7P>5
M]J?HA[Y?[U%+^:.C^6/*NBV0C:^U(6,#-`C!5CK&*>H^_$G^4+RR'\G3S99'
MZ8\<FW^6<>FP8X_7D\./I_S?XD'IWY^P/,%U#23'$3O)!*'('^JRI7_@LLGV
M+*O3)IQ>U$2?7#A']$\3T[1]8T[6-/BO].F6>VF%5<=01U5@=U8=U.:?+BE"
M7#(47I<&>&6`G`\42QIOS-T]?.'^%_J<QN?7$'UBJ>G4KRK2O+,H:"1P^+8J
MG7'MB`U'@<,N*^'B97>WUI8VDMY>2K!;0J7EE<T50,PX1,B`-R7:9,D81,I'
MAC%YEJWY\Z?%.8M*TU[M`:":9_2#>ZH%=O\`@N.;?'V-(CU2$?\`9/-Y_::`
M-8XF?^Q5-$_/72+F=8=6LGL`QH;A&]9`?\H45P/H;!F['F!<3Q?[%EIO:7'(
MUDB<?]+ZWIL$\-Q"D\#K+#(H:.1""K*14$$9J""#1>DC($6.3__2]4XJPO\`
M.#RKHOF3R#JEMJLR6B6L37EO?R=()85+*Y_R3NCT^TC9?I\AC,$-.>`E`V^%
MQTSH'1OK/_G%K1/+EOY(FU:QE6XUB]F:/5&(H\/I']W`._'B?5Y?M\_\G--K
MY2,Z/)VVCB!&QS>TY@N8[%7S9_SE_P#[U>5O]2\_7#FT[.Y2^#KM?T0W_.(?
M_'=\Q_\`,+;_`/)Q\/:/((T',OIJ;^Z?_5/ZLU0=D_.:;[4GS;]>=.\]U?HE
MI?\`QS+3_C#'_P`0&<R>;T`Y(G`EY-^?W^\FB_\`&2?_`(BF;OL7ZI?!Y7VI
M^B'OE_O49^4'DK2TT*/7+ZV2XOKPL8&E`<1Q*>*\0=@S<:\LK[4U<C,P!J,6
M[L'LZ`Q#+(<4Y_SOX8LN\S^2]#U[3)K6>UB2=E/H7*(JR1O3X6#`5I7[2Y@X
M-7/%($';^:[;6=GXL\#$@7_#+^:\M_);5KK3_--UH4S'TKE9.25V6>W[CYJ&
M'_`YN>UL8GB&0?P_[F3S'L[GECSRPGE+_=P4Y?\`R>0_YCU_Y-#&/^)?YO\`
MOF,O^-3_`#_]ZC?SNU^ZN=4M/+ML28HU6::-?VYI#2-3X\5Z?Z^0['P@1.0_
MB+=[2:F4LD<,?ZTOZTOI>A^2O).E>7-*AB6!'U!E#7=VR@NTA'Q`$[A%Z*N:
MO5:N6:1-^G^&+T'9_9V/3XP`/7_%-`_F)Y$TS7-&N)X+=(M6MT:6WG10K.5%
M3&]/M!Z4%?LMEFAULL4P"?0?J:>UNS(9\9('[R.\9?[UB_Y%>8YY4O-`G<LD
M"_6;,'JJEN,BC_)Y%6_V39F]L8`",@Z^F7^]=9[-:PR$L4OX?5#_`'S_`/_3
M]4XJ^:/^<GOS0^L7`\C:5+^X@*RZW*AV:0?%';[=DVDD_P`O@O[#9M=!@KUG
M_-==K<W\(>1Z-^77F+5O)6L>;K6.NG:.Z)(M#RD!WF9/:!2C2?ZW^3F;+-&,
MQ$\Y.)'`3$R[D[_)'\RW\C^;4>Z<_H+4N,&II4T05_=S@>,1/Q?\5\\JU>#Q
M([?4&>ES<$M^1?:\<D<B+)&P>-P&1U-00=P01XYHG<MXJ^;/^<O_`/>KRM_J
M7GZX<VG9W*7P==K^B&_YQ#_X[OF/_F%M_P#DX^'M'D$:#F7TU-_=/_JG]6:H
M.R?G--]J3YM^O.G>>ZOT2TO_`(YEI_QAC_X@,YD\WH!R1.!+R;\__P#>31?^
M,D__`!%,W?8OU2^#ROM3]$/?+_>LX_+SA_@C1>'V?JJ5^=-_QS7:W^^E?\YW
M?9?^+0_JAD.8I<]X'Y"7UOS<9XS\"W-[)4=.-)!_'.EUFVD`/=#]#PO9F_:!
M(_G9/]\KR_\`D\A_S'K_`,FAD(_XE_F_[YG+_C4_S_\`>J/YAGT?S8CEF($0
MFL7J>@0!*_J.3T(O2T.Z;'M7;M`$\N+'_O7O><T]RME=$B=W-$526)Z4`J<(
M030>$_DD.7G:X9!\`M)C7V,B4SI>US^Y`_I/#>S@O4D_T)?[J+__U.X_G!^8
MT'D7RC-?H5;5KNMOI4!WY3$?;(_DA'QO_L4_;R_38?$E73JTY\O!&WQAHVDZ
MSYJ\R6^G6Q:ZU75KBAE<DDO(2TDKGP7XI';-[*0A&^D731B9RKO?=GE?RCI'
ME[RK:>6[6(/86\'HR!P/WI<'U7<=S*Q9F_ULYZ>0RD9%WD(",:?&?YN_E_+Y
M(\YW6F(I.F7%;G2Y34U@<_8KW:)OW;?[%OVLWNFS>)&^O5T^HQ<$O)[G_P`X
MR_F:=7TAO*&IS<M2TM.6G.YWEM!MPWZM`33_`(Q<?Y,U^OP4>(<I.=H\W$.$
M\P]TS7N:^;/^<O\`_>KRM_J7GZX<VG9W*7P==K^B&_YQ#_X[OF/_`)A;?_DX
M^'M'D$:#F7TU-_=/_JG]6:H.R?G/**R./\H_KSIWG7J$/_.2OYK0PI$EY:!(
MU"*/JJ=%%!WS#_(XW+_.37_]#-?FS_RV6G_2*G]<?R.-?SLU2#\TO-_G=S#Y
M@FAE2Q'.W]&%8J&0T:M.NRYGZ'3QQD\+H.W\\IQA?>7K_P"77YD6^@6*:%YC
M22VCB`>SN>!8"*7XP'"_%Q^+DCKR^%LP]=H#E/B8]_YSD=D]K#!$8L_HKZ)?
MT9>I/?-OYQ^7[;398M#F-[J$JE8G"LL<9(IS8N%KQ[*N8^F[*R2E<_3%S==[
M0880(Q'CF?\`2Q2W\D?*=U!Z_F*]0I]83T;(.-V0D%Y-^S4"K_LLL[7U()&,
M=/J_XEQ_9S02C>:7\7IA_P`4D<O_`)/(?\QZ_P#)H9D1_P`2_P`W_?.#+_C4
M_P`__>LB_.CR;<W]O#K]C&9);2/TKR)!5C""660`;G@2>7^3_JYB]DZL1/AR
MY2^G^L['VA[.ED`RP'JA]?\`4_XZJ>2?SBT5]+@L]?F:UOH%"&Y*LT<H44#5
M0$J]/M?#CJ^RYB1.,<43_L4]G=OXC`1RG@G'^+^<@_S"_-S2[C2I]*\ONT\E
MTIBGO"I1%C848)R`9F8?#]GX<LT/9DA(3R;</\+3VKV[`XSCPGBE/^)-_P`G
M?)MUHNF3:E?QF*]U#B$A;[4<*[KR'9G)Y%?]7*.U-6,DA&/TP_W3E]@=GRP8
MS.>T\G^X?__5]%>9/(/D[S-<0W&OZ5#J,UNAC@:;D>"L:D*`0!4Y9#+*/(TP
MECC+FHZ!^6GD/R_J`U'1=$MK&^5&C6XB4\PK_:`))I7#/-.0HE$<48FP&2Y4
MV)+YE\E>5/,ZP+K^EP:B+4L;?UEJ4YT#4(H=Z#)PRRCR-,)0$N:7:1^5/Y=Z
M/J,&I:7H5M9W]L2T%Q$&5U)!4T/+N#3)RSSD*)V0,,0;`97E+8D?F7R-Y1\S
MM;MK^EPZBUJ&%N9@3P#TY4H1]KBN60RRCR-,)8XRYA;Y:\A^3_+,T\V@:5!I
MTMRJI.\((+JI)4&I/0G&>64N9M8XXQY)\0""#N#L1E;-A)_)/\J"23Y9LZG<
M_"W_`#5E_P"9R=[5X$.YK_E27Y4?]2S9?\"W_-6/YG)WKX$.YW_*DORH_P"I
M9LO^!;_FK'\SD[U\"'<B;/\`*+\M;)G:U\OVL)<`.55A4#Z<E'691RD6G+H<
M.3ZHB5)CK'DCROJ]K#;7U@CI;((K=UJDD:**!5=2&XBG3!BU>3&28GFQU'9^
M#-$1G'Z=HI=IWY4^1K"<3)I_KN*%?K#M*H(W^RQX_>,NR=HYI"N*OZKCX>Q-
M+C-B-_UO4RU5"J%444;`#H!F"[5*3Y2\MG5OTN;"(ZGS]3ZU0\^8%*]?#+OS
M.3@X+]/\UQ?R6'Q/$X1XG\Y-Z"E.V4N4Q75ORP\E:I<&XGT\13L:N]NS0\B>
MY5"%_#,S%VAF@*$MOZ7J=9G['TV4V8[_`-'TJNB_ESY.T>=;BST]3<*:I-,6
ME93_`)/,D+]&#-KLN049;,M-V5I\)N,?5_.EZF2YB.Q?_];U3BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__7]4XJ[%78J[%78J[%
?78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
